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1. Introduction 
The mammalian pregnancy is an immunologic challenge to the maternal immune system. 
Considering the fact that transplant rejection is a well-defined immunologic phenomenon, 
the peaceful feto-maternal coexistence during mammalian pregnancy has been defined as “a 
paradox of nature” and puzzled immunologists for ages. In 1953, the immunologist and 
Nobel Prize laureate Sir Peter Medawar proposed that the maternal immune system is 
ignoring the fetus and defined his three well-known mechanisms for achievement of this: 
anatomical separation of the fetus and the mother, fetal antigenic immaturity and maternal 
inertness or indolence to the fetus (1). Although Medawar’s proposal is still recognized and 
cited, it is only partly true and has been rightly revised in recent years. Today, it is well-
proven that instead of being ignored, pregnancy is indeed recognized but tolerated by the 
maternal immune system, however, the responsible mechanisms for that remain unknown. 
The maternal-fetal interactions are highly complex and cannot be explained by, or 
subordinated to a single uniting theory of maternal tolerance to the fetus. In stead, multiple 
mechanisms, operating in concert at the systemic- as well as the local level are moulding the 
framework of successful pregnancy (reviewed in 2). Several of these mechanisms are 
mediated by the placenta, the key organ for successful mammalian reproduction (2).  
Apart of its function as a hormonal, nutritional and oxygen provider of the fetus, placenta 
stands out as an important immunomodulatory organ actively secreting signal substances 
and factors that alter the maternal immune responses during pregnancy. Recently, several 
reports have shown that the human placenta participates in the feto-maternal cross-talk by 
secretion of nanometer-sized endosomally produced membrane-bound microvesicles (MV) 
called exosomes that act as fetal messengers and transfer packages of information to the 
maternal organism for adaptation to the ongoing pregnancy (3-8). The main focus of this 
chapter is on placenta-derived exosomes and their role in reproduction. A comparison to the 
placenta-released exosomes, larger placental microvesicles/microparticles, which are shed 
from the apical cell membrane of syncytiotrophoblast, will be presented and discussed. 
Initially, as a background, a short description of cell-cell communication and various 
microvesicles and their generation and roles is given. 
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2. Cell-cell communication – A basic necessity for all living organisms 
Communication between individual cells is imperative for all living organisms. For a long 
time, cell communication was considered to be effectuated by three different ways: 1) by 
direct adhesion contacts between cells, such as receptor-ligand signalling and trogocytosis; 
2) by soluble mediators, such as hormones, cytokines, chemokines and other signalling 
substances, bioactive ions and lipids, released in an autocrine and paracrine manner; and 3) 
by shuttling of information through intercellular channels called nanotubules (9, 10).  
Recently, however, attention was focused on the fourth way of intercellular communication 
built on release and uptake of membrane-bound MVs. Communication by MV combines 
secretion of molecules with preservation of their membrane attachment and three-
dimensional structure thus preserving the biologic activity of these molecules. Secreted or 
shed MVs execute cell-cell contact “by proxy”, delivering information from a donor to a 
recipient/target cell in the near vicinity or at a distance. The exosomes are the smallest 
members of the MV family and the only ones that are produced in the endosomal 
compartment in multivesicular bodies (MVB) and secreted by exocytosis in the intercellular 
space, blood and various bodily fluids. The function of exosomes is highly diverse and 
dependent on the cells from which they originate. One very prominent feature is their 
immunomodulatory potency (reviewed in 9, 10). The rest of the MVs are larger in size and 
are produced and released from the plasma membrane by shedding or blebbing. 
2.1 Microvesicles are everywhere  
The existence of various membrane-bound MV in the intercellular space is easily observed 
by electron microscopy but for a long time was considered to be inert debris from cellular 
damage and of no importance. Thus, the first descriptions of exosome-like microvesicles 
during the 1980s by Heine et al. and Jonstone et al., who also named them exosomes and 
pointed out a biological role for these vesicles, were completely ignored (11-13). Only 
recently, less than 10 years ago were they rediscovered and identified as tools for 
intercellular communication. The realization that there are MVs produced by various cells 
and found in the blood and all bodily effusions in both health and disease has opened new 
perspectives in biology, understanding cell-cell communication and various biological 
mechanisms and their regulation. The MVs are a heterogeneous group, released both in 
health and disease. Their composition depends on and reflects the state of the cells that 
produce them and their physiological and/or pathogenetic roles are diverse depending on 
the donor cells, the recipient cells and in what environmental context they act. MVs are 
divided by size, morphology and mode of generation into (i) large MV, produced by 
budding of the cellular membrane, 0.1-2 m in size with various roundish, oval or elongated 
shapes and (ii) small, nanosized (30-100 nm) MVs of endosomal origin called exosomes that 
will be separately discussed. The large MVs comprise two main types: those, produced by 
budding from the plasma membrane of living cells, including shed microvilli, called 
microvesicles or sometimes microparticles (14, 15); and those, produced by 
blebbing/fragmentation of the plasma membrane during the programmed dying of the 
cells, called apoptotic bodies/apoptotic blebs/apoptotic vesicles (16). 
MVs, including exosomes, are produced by a vast variety of cells. Their “rediscovery” and 
upgrading in importance have caused a huge, exponential interest among scientists and 
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literally an explosion of reports in the literature describing the MVs under different names, 
which can create confusion. In Table 1 a glossary with the names and definitions of various 
MV, described in the literature are given. The physical and morphological characteristics of 
the main MV types are presented in Table 2.  
 
Microvesicle 
designation 
Definition 
  
Apoptotic 
bodies/blebs/ 
microvesicles/ 
microparticles 
Microvesicles produced by fragmentation of the plasma membrane and 
the soma of dying cells. Carry membranal and cytosolic proteins and 
nucleic components like DNA. 
Cardiosomes Term used to designate exosomes produced by cardiomyocytes 
Ectosomes Vesicles shed from the plasma membrane of neutrophils and fibroblasts. 
Endosomes Nanovesicles (<100 nm in size) present in the multivesicular bodies 
(MVB), produced by inward budding of MVB’s limiting membrane and 
secreted by exocytosis; called exosomes in secreted form. 
Exovesicles Microvesicles shed from the plasma membrane of dendritic cells. 
Exosomes 30-100 nm-sized vesicles of endosomal origin secreted by fusion of MVB 
with the plasma membrane. Produced by a great variety of healthy and 
tumor cells and by the syncytiotrophoblast of the placenta. 
Microparticles Microvesicles shed by platelets, monocytes, and by the apical part of the 
syncytiotrophoblast plasma membrane, should not be confused with the 
syncytiotrophoblast-derived exosomes that are secreted through the 
exosomal compartment. 
Microvesicles The term is used in two ways: to designate all types of membrane-bound 
microvesicles, including exosomes and/or to designate larger 
microvesicles (>100 nm) produced and shed by the plasma membrane of 
normal and abnormal cells. 
Prostasomes Microvesicles of around 600 nm to 1m in size, produced by shedding 
from the plasma membrane of normal prostate gland epithelium. 
Presence of prostasomes in prostate secretion is associated with fertility. 
However, the term has been used in a substantial amount of publications 
to designate exosomes. 
Prominosomes Microvesicles produced from the plasma membrane of the stem cells in 
the neural tube and the brain 
STBM Syncytiotrophoblast microvesicles or microparticles produced by the 
apical part of the plasma membrane, see microparticle definition above. 
Tolerosomes Exosomes, produced by the epithelial cells in the gastro-intestinal tract, 
involved in oral tolerance 
Vexosomes Microvesicles/exosomes engineered in vitro to carry viral vectors for 
gene therapy 
Table 1. Glossary for terms and definitions used in scientific publication for description of 
microvesicles 
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Characteristics Exosomes Microvesicles/ 
Microparticles 
Shed microvilli Apoptotic 
bodies/vesicles 
Size 30-100 nm 0.1-2 m > 400 nm 100–600to700 nm 
Density in 
sucrose  
1.13 – 1.19 g/ml Undetermined Undetermined 1.16-1.28 g/ml 
Sedimentation (g) 100,000 -110,000 10,000 -100,000 10,000 1,500 – 100,000 
Morphological 
shape 
Cup shaped, 
electron translucent 
Various shapes, 
electron-dense 
and/or electron 
translucent 
Various shapes, 
round, 
elongated and 
cylinder-like 
Irregular and 
heterogeneous in 
shape 
Lipid membrane 
composition  
Cholesterol-, 
sphingomyelin-, and 
ceramide-rich lipid 
rafts, expose 
phosphatidylserine 
Expose 
phosphatidylserine, 
some enriched in 
cholesterol and 
diacylglycerol, 
some undetermined 
Undetermined Undetermined 
Specific marker(s) 
for identification 
Tetraspanins (CD63, 
CD9, CD83), ESCRT 
complex members 
(Alix, TSG101) 
Integrins, selectins, 
CD40 and others, 
depending on the 
cell type 
Various, 
depending on 
the cell type 
Histones, DNA 
Origin in the cell Endosomal 
compartment - 
multivesicular bodies 
(MVB)  
Plasma membrane Plasma 
membrane 
Fragments of 
dying cells, 
undetermined 
Mechanism of 
sorting 
Ceramide and 
ubiquitin dependent 
Unknown Unknown Fragments of 
dying cells, 
undetermined 
Intracellular 
storage 
Yes No No No 
Mode of 
release/secretion 
Exocytosis by fusion 
of MVB with the 
plasma membrane 
Plasma membrane 
blebbing 
Plasma 
membrane 
blebbing 
Plasma 
membrane 
blebbing and 
cellular 
fragmentation 
 
Adapted from ref. 10 with permission of Expert Reviews Ltd 
Table 2. Some of the main characteristics of different types of microvesicles.* 
2.2 Exosomes: definition and biogenesis  
The exosomes are the smallest MVs that are produced in the multivesicular bodies (MVB) in 
the endosomal compartments of individual cells and secreted into the extracellular space by 
www.intechopen.com
 Placenta-Derived Exosomes and Their Role in the Immune Protection of the Fetus 
 
247 
exocytosis. The exosomes are membrane bound nanometer-sized vesicles that carry a 
variety of proteins on their surface as well as inside, mRNA and microRNA and can be 
compared to parcels sent as “mail” between cells. The late endosomal compartment, where 
they are generated, can be viewed as “the post office”. Each exosome carry proteins on its 
surface that serve as addresses of the sender and the recipient cell. Recent accumulating 
evidence shows that this “mail” can be powerful and transforming, determining the fate of 
the recipient cell.  
The current definition of exosomes is: secreted membrane-bound nanovesicles that carry the 
following characteristics: 1) cup-shaped form, 2) 30-100 nm size, 3) tetraspanin presence in 
their lipid rich membrane, 4) buoyant density of 1.13-1,19 g/ml on sucrose gradient and 5) 
endosomal origin (9, 10). 
The suggested pathway of biogenesis of exosomes separates them from all other known 
MVs. The exosomes are produced in the late endosomal compartment by inward budding of 
the limiting tetraspanin- and lipid-rich membrane of MVB and contain surface-bound and 
cytosolic proteins and RNA molecules. They are released when the MVB membrane fuses 
with the cellular plasma membrane and the MVB content of exosomes is emptied into the 
extracellular space. A detail schematic presentation of exosome biogenesis is shown in 
Figure 1B. There are two major pathways by which proteins are sorted to the MVB 
membrane that by inward budding becomes exosomal membrane: (i) protein recycling by 
endocytosis and transport of plasma membrane-expressed proteins to the early recycling 
endosomal compartment and from there to the late endosomal compartment and eventually 
to the MVB ending up on exosomes and (ii) direct transportation of proteins from the Golgi 
complex to the MVB where they are inserted into the MVB limiting membrane and further 
become expressed on the exosomal membrane as exosomes are produced in the MVB by 
inward budding. Previously, MVB were solely considered as an intermediate stage in the 
maturation of endosomes to lysosomes and were ascribed to be a “garbage station” of the 
cell – a dustbin for proteins aimed for destruction. Today it is known that instead of the 
lysosomal protein-destruction route, MVB can take an alternative route, moving to the 
plasma membrane and by fusion with it releasing their nanovesicle cargo as exosomes in the 
extracellular space. Thus, MVB are endosomal cellular organelles situated at a cross road in 
the cell where the fate of the proteins sorted to the MVB is decided – secretion by exosomes 
or degradation in lysosomes. Accordingly, two types of MVB have been suggested – 
degradative MVB taking the lysosomal pathway and exocytotic MVB involved in the 
secretion of exosomes. The process of sorting proteins to degradative MVB involves a 
multiprotein network called endosomal-sorting complexes required for transport (ESCRT) 
and ubiquitinylation process that tags with ubiquitin both cell surface and cytosolic proteins 
targeted for lysosomal degradation (17, 18). At present, the mechanism underlying the 
exocytotic MVB trafficking to the plasma membrane is less clear. The transmembrane 
protein TSAP6 is suggested to regulate exosome formation and Rab11, a member of the 
small GTPase family and calcium are considered to participate in the docking and fusion of 
exocytotic MVB with the plasma membrane (19, 20). Two pathways for protein sorting for 
exosome secretion have been suggested – the ESCRT multiprotein complex and an 
alternative ubiquitin-independent pathway based on sphingomyelin metabolites such as 
ceramide (18, 21). More studies are needed to establish the link between ubiquitin, 
phospholipids and ESCRT proteins and their role in the biogenesis of exosomes.  
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Adapted from reference #10 with permission of Expert Reviews Ltd. 
Fig. 1. Generation of different microvesicles and their main characteristics. A) Shed 
microvilli, microvesicles and apoptotic bodies are all generated by the plasma membrane. B) 
Exosomes are generated in the endosomal compartment and carry both recycled proteins 
and proteins produced in the rough endoplasmic reticulum (RER) and directly sorted to the 
multivesicular bodies (MVB) from the Complex Golgi (CG). Note how the proteins are 
internalised in coated pits or inserted in the limiting membrane of the MVB and how 
exosomes are produced by inward budding of the limiting membrane – a way that ensures 
the same orientation of the membrane bound proteins on the exosomal membrane as that on 
the plasma membrane of the cell. The exosome-filled MVB are either fused with the plasma 
membrane to release exosomes or sent to lysosomes for degradation. The mechanisms 
deciding excretion or degradation of MVB are at present not known. 
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2.3 Exosomes: morphology, general biochemical composition and suggested roles 
Electron microscopy is the method of choice for studies of exosomes biogenesis and 
morphology. Visualized in situ the exosomes are uniform spherical vesicles of 50-90 nm in 
size situated within the lumen of MVB. The electron microscopy image of isolated exosomes 
is different- the size varies between 30 to 100 nm, which is the upper size limit of exosomes 
and they have a typical cup-shaped form that is their hallmark. An illustration of isolated 
exosomes showing the typical heterogeneity in size and the cup shape is given in Figure 2A. 
The reason for the cap shape appearance is not known, but might be a consequence of the 
isolation procedure. The exosomal membrane is detergent and low temperature resistant 
and consists of lipid-rich bilayer of cholesterol, sphingolipids and tetraspanins where 
proteins with transmembrane or glycosylphosphinositol linkage are inserted. 
Exosomes consist of proteins and RNA. The composition of the exosomes depends on the 
cells that have produced them and can vary even within the same cells, depending on their 
current differentiation and activation status. Thus exosomes reflect their donors and can 
influence their recipients. There is a conserved set of proteins common to all exosomes – 
cytosolic proteins such as tubulin, actin, actin-binding proteins, annexins, Rab proteins, heat 
shock proteins, signal transduction kinases, heterodimeric G proteins and the ESCRT 
members ALIX and TSG101. Common proteins expressed on the exosomal surface are 
adhesion molecules such as integrins and ICAM-1, MHC class I, and the tetraspanins like 
CD9, CD63, CD81 and CD82 (22). 
There are many advantages of exosome-mediated cell-cell communication that can be listed 
as follows: (i) preservation of the 3D structure of the transported proteins and thus their 
biological activity; (ii) independence of cell-cell contact for signal delivery; (iii) 
independence of de novo synthesis; (iv) packages of carried molecules with a lower mobility 
and a higher concentration of the carried molecules; (v) biological effect at a distance.  
Exosomes have been ascribed a variety of biological functions such as intracellular 
signalling, antigen presentation, immune regulation, receptor-ligand interactions, pro- and 
anti-apoptotic effects, delivery of proteins to plasma membrane of recipient cells thus 
changing their adhesive properties, transport of bioactive mRNA and microRNA, thus 
regulating gene expression and reprogramming recipient cells.  
Exosomes can be divided into two major groups in relation to the immune defence system – 
exosomes with immunoactivating properties and those that are tolerogenic or 
immunosuppressive. In general, exosomes produced by immune cells such as antigen 
presenting cells (macrophages, dendritic cells and B cells) are immunoactivating. They can 
activate in various ways such as (i) directly by functioning as antigen presenters by proxy or 
indirectly by initiating immune response via dendritic cells that take up the exosomes and 
process the antigens carried by them; (ii) by activation T helper cells to cytokine production; 
(iii) by boostering cytotoxicity, antibody and cytokine production or priming of T cells 
(reviewed in 9, 10, 23). Interestingly, the cytolytic molecules perforin, granzyme and 
granulysin as well as FasL that are components of the cytotoxic machinery of cytotoxic T- 
and NK cells, are carried by exosome-like specialised vesicles in secretory lysosomes (24). 
The exosomes produced by epithelial cells and by the great majority of tumors are immune 
inhibitory. Normal epithelium secretes low amounts of exosomes that exert a mild 
immunosuppressive effect promoting homeostasis and immune tolerance. In contrast,  
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Bars represent 100 nm.  
Reproduced from reference #10 with permission of Expert Reviews Ltd. 
Fig. 2. Isolated exosomes from supernatants of placental explant cultures. A) Negative 
contrast staining showing their size and the typical cup-shaped form. B) Isolated exosomes 
stained with antibodies against the NKG2D ligands MIC and ULBP1-2 and immunogold.  
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epithelialy derived tumors such as various carcinomas secrete high amounts of 
immunosuppressive exosomes that carry immunoinhibitory molecules, proapoptotic 
molecules and receptor ligands that serve as decoys, dysregulating normal immune responses 
and impairing the immune system of the host. Thus the net effect of tumor exosomes 
originating from mammary, lung, colon, prostate and ovarian cancers is a powerful immune 
inhibition promoting the primary tumor to establish itself and spread metastases (25). Similar 
to tumors, placenta-derived exosomes, produced by the syncytiotrophoblast are suppressive 
and able to modulate the maternal immune system.  
3. Human syncytiotrophoblast-a source of plasma membrane-derived shed 
microvesicles and endosomally secreted exosomes 
The human syncytiotrophoblast, covering the placental villi, is the most important cell type 
of the human placenta with several functions such as being (i) the chief regulator of oxygen 
and nutritional and waste transport between the fetus and the mother necessary for fetal 
survival and growth; (ii) the site of synthesis of a variety of proteins – such as steroid and 
placental protein hormones, adhesion molecules and matrix metalloproteases, signal 
substances, and immunomodulatory molecules of crucial importance for the pregnancy 
success (26, 27). The syncytiotrophoblast is responsible for and carries out the “cross talk” 
between the mother and the fetus during pregnancy.  
The human syncytiotrophoblast comprise a continuous layer of multinucleated finally 
differentiated trophoblast that makes a syncytium covering completely the multitudinous 
chorionic villi. The free apical part of the syncytium that is in direct contact with the 
maternal blood, is richly covered with numerous highly pleomorphic microvilli and 
branched surface projections suggesting a high mobility of the apical part of the 
syncytioplasm (27, 28). Comprehensive electron microscopic studies have shown that there 
is a constitutive shedding activity of plasma membrane-bound microvesicles and even 
whole microvilli from the apical syncytiotrophoblast surface membrane to the maternal 
blood. This normal shedding activity becomes forcefully enhanced by stress enforced by 
various pathologic pregnancy conditions, the most well-known and studied being 
preeclampsia (29). Besides the intensive shedding activity from the apical membrane surface 
the syncytiotrophoblast has an elaborate endosomal compartment and a high protein 
turnover activity. Scattered between the villi are numerous bristle-coated pits or caveolae, 
lipid-rich spots on the plasma membrane, associated with membrane molecule uptake and 
recycling. The syncytioplasm is very rich in free ribosomes and rough endoplasmic 
reticulum with dilated cisterns, Golgi complexes distributed at intervals in the syncytium 
and numerous mitochondria and tubular and numerous endosomal membranes and 
multivesicular bodies, all characteristic of vigorous protein synthesis and a well-developed 
endosomal compartment. The features of active protein synthesis, protein uptake and 
recycling and the elaborate MVB-rich endosomal compartment warrant for biogenesis and 
release of exosomes. Numerous nanometer-sized vesicles are seen in the MVB that reach the 
apical plasma membrane and open up to release their content. Thus, in addition to MV 
shedding from the plasma membrane, the syncytiotrophoblast of the human placenta 
simultaneously and constitutively releases exosomes. 
The first provided ultrastructural evidence of biogenesis of exosomes in human placenta 
was shown for FasL and reported by Frängsmyr et al. (4). Using immunoelectron 
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microscopy (IEM), it was shown that expression of FasL was completely devoid from the 
syncytioplasm and in stead directed to the MVB in the syncytiotrophoblast and secreted by 
exosomes of 60-100 nm in size (4). Furthermore, the NKG2D receptor ligands MHC class I 
chain related antigens A and B (MICA/B) and the human retinoic acid early transcript 1 
(RAET1) proteins, also known as UL-16 binding protein (ULBP) 1-5, were used as marker 
molecules of the endosomal compartment in studies of the biogenesis of exosomes in the 
human syncytiotrophoblast (7, 8). Representative micrographs shown in Figure 3, illustrate 
MICA/B molecule expression in human syncytiotrophoblast. As can be seen in Figure 3A, 
besides surface expression these molecules are sorted to numerous MVB at different levels 
in the cytoplasm. Frequently, fusion of MVB with the apical microvillous membrane of the 
syncytiotrophoblast and release of microvesicles was seen (Figure 3B).  
 
MICA/B: MHC class.I chain-related molecules A and B; MVB: multivesicular body. 
Magnification: A) X 18,000; B) X 25,000. 
Fig. 3. Biogenesis of MICA/B-expressing exosomes in the syncytiotrophoblast of human 
early normal placenta. A) Electron micrograph showing the apical microvillous surface and 
MVB stained with anti-MICA/B-antibodies. One of the MVB (arrow) is opening and 
releasing exosomes in the intervillous space. B) A magnification of MVB filled with 
exosomes and stained for MICA/B. Note also the staining of the limiting membrane. 
Arrows point at exosomes.  
A logical question is how is it decided if a protein will be sorted to the endosomal 
compartment for exosome secretion? From our studies of exosome biogenesis in the 
syncytiotrophoblast (4, 7, 8) we propose two possible ways: (i) Proteins with lysine residues 
in their cytoplasmic tail such as MICB, FasL, ULBP4 and 5 are controlled by ubiquitinylation 
and will be sorted preferentially to MVB (30, 31). In support of this suggestion, we have 
reported that members of the ESCRT complex localize in the syncytiotrophoblastic MVB (8). 
(ii)By contrast, glycosylphosphoinositol (GPI)-linked proteins, such as ULBP1-3 and the 
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transmembrane MICA are preferentially expressed in lipid rafts at the cell surface and by 
recycling can be sorted to the MVB. Such lipid raft domains have been proposed to support 
sorting of proteins to MVB and formation of exosomes (32, 33). In our studies (4, 7, 8) we 
found frequently lipid rafts and caveolae in the apical surface of the syncytiotrophoblast. In 
summary, we can conclude that both plasma membranal and exosomal expression of 
proteins is occurring in the human syncytiotrophoblast. The rich endosomal compartment 
with numerous MVB and the frequent signs of exosome release from the apical surface 
suggests that exosomal secretion is a constitutive feature of the villous syncytiotrophoblast. 
The next question is if there is an advantage of exosomal secretion in pregnancy? Our 
studies of apoptosis-inducing molecules and the stress-inducible NKG2D ligands in human 
placenta clearly show that exosomal secretion is chosen over plasma membranal expression 
of these molecules and this choice is of crucial importance for the protection of the fetal 
allograft. If the apoptosis-inducing FasL was expressed on the cell surface, it would be 
immediately cleaved by the richly expressed placental matrix metalloproteases. The 
resulting soluble FasL would be easily involved in induction and promotion of unwanted 
inflammatory responses at the fetomaternal interface in a similar way as it promotes 
autoimmune inflammation and hypergammaglobulinemia in a systemic lupus 
erythematosus-like syndrome (34). In stead, exosomal FasL expression provides a 
membrane-bound form of the molecule that induced apoptosis of activated immune cells 
and thus promotes immunotolerance (4-6, 34). Furthermore, a strategy of releasing NKG2D 
ligands by placental exosomes would be a decoy mechanism downregulating the activating 
NK cell receptor NKG2D; by contrast a membranal expression of these molecules would 
make the villous syncytiotrophoblast a target for attack by NKG2D receptor-bearing 
maternal cytotoxic T and NK cells (7, 8). In conclusion, (i) the syncytiotrophoblast of the 
human placenta is a site of exosomal biogenesis and release; (ii) the exosomal secretion of 
important immunomodulatory molecules promotes the survival of the fetal allograft and is 
thus preferentially used by the human placenta as a fetal immune escape mechanism. In 
addition, the human syncytiotrophoblast is a vigorous protein produced with a MVB-rich 
endosomal compartment and thus an excellent model for studies of exosome biogenesis per 
se.  
4. Placenta-derived exosomes: composition, structure and function  
4.1 Methodological considerations in experimental work with exosomes 
The difficulties in characterizing placental exosomes so far lie in the fact that the villous 
syncytiotrophoblast, which is the main exosome producer, simultaneously sheds 
microvesicles, sometimes called STBM or microparticles, from the apical plasma membrane. 
In several studies, a crude bulk of ultracentrifuged pellets are analysed as exosomes. It is 
important to realize that such pellets contain all kinds of large MVs, apoptotic bodies, other 
particles and protein precipitates together with exosomes. Thus, it is of extreme importance 
to pay attention to the isolation procedure when separating placental exosomes for 
characterization of their biochemical composition and functions. Firstly, it is absolutely 
necessary to apply a continuous sucrose gradient (floating density 1.13-1.19) or a sucrose 
cushion to ensure enrichment and collection of “maximally pure” exosomes. Secondly, 
when immunoflow cytometry is used for phenotypic characterization of molecules on the 
exosomal surface, an indirect approach by loading of the exosomes on beads should be 
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applied, since most of the fluorescence-activated cell sorters have a discriminative capacity 
of around 300 nm and thus will exclude free unbound exosomes run directly in the cell 
sorter. Thirdly, the isolated fraction that is believed to be exosomes must be confirmed by 
analysing exosome specific markers, such as CD63, CD81, TSG101 and Alix. 
4.2 Exosomal structure and composition 
So far, studies of isolated placental exosomes have been performed on populations 
separated from placental explant cultures (7, 8) and peripheral blood of pregnant women (4, 
5). Figure 2 illustrates syncytiotrophoblast-derived placental exosomes visualized by 
negative contrast staining and immunoelectron microscopy. The morphology is the typical 
cup shape and the size varies between 40 and 90 nm (Figure 2A). IEM reveals that they 
express the tetraspanins marker CD63 and the placenta-specific marker placental alkaline 
phosphatase, indicating their placental origin. In contrast to other exosomes, the placental 
exosomes are devoid of classical MHC molecules. Instead, they carry on their surface the 
stress inducible non-classical MHC class I chain-related molecules MICA/B and 
RAET1/ULBP1-5, ligands of the major cytotoxic receptor NKG2D (7, 8 Figure 2B). Besides 
the NKG2D ligands, placental exosomes express proapoptotic molecules such as FasL, 
TRAIL, and PD-L1 (3-6). In addition, they display a membranal expression of the regulatory 
cytokine TGF. Recently, we performed proteomic analysis on placental explant culture-
derived exosomes. An illustration of the major protein components are presented in Figure 
4. In principal, the protein content can be divided into two compartments: proteins present 
on the exosomal membrane and those, entrapped in the exosomal lumen. The proteomic 
analysis revealed cytosolic proteins involved in biosynthesis and degradation, intracellular 
transport, fusion and signal transduction, heat-shock proteins and chaperons, and enzymes 
and ESCRT-associated proteins associated with exosome formation such as TSG101, Alix, 
vascular sorting protein 29 and charged MVB protein 1B and 4B (9, 10).  
 
Fig. 4. Schematic presentation of a placental exosome and a list of some proteins, specific for 
placental exosomes. 
Exosomes can transport selected mRNA and miRNA molecules from donor to recipient cells 
and thus influence and genetically reprogram recipient cells and regulate their intracellular 
metabolic pathways. So far, there are few studies of RNA content in placenta and placental 
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exosomes. The first detailed miRNA study of placenta revealed that most placenta specific 
miRNAs were localized at a miRNA cluster on chromosome 19 (35) and were up- regulated 
during placental development. Six novel miRNA were identified and 4 of them were 
placenta-specific. Placenta-specific miRNA was also identified in plasma from pregnant 
women (36). Urged by these reports, exploration of miRNA content in placenta exosomes 
was undertaken. The trophoblast-derived cell line BeWo was used as a source of exosomes. 
Two placenta-specific miRNAs, MIR517A and MIR21 were found in the exosome-enriched 
supernatant fraction from BeWo cultures. A possible involvement of MIR17A in the 
regulation of TNF signal transduction has been suggested. This is the first and so far only mi 
RNA investigation of trophoblast-derived exosomes. Thus, these results need to be repeated, 
confirmed and extended to exosomes from placental cultures and normal and pathologic 
pregnancies at different times of gestation and of placenta differentiation. Thus, placental 
exosome-derived mRNAs and miRNAs and their capacity to enter and reprogram maternal 
cells awaits to be elucidated in future studies.  
4.3 What do placental exosomes do? 
As mentioned previously, the importance of enriching maximally pure exosome fractions 
for functional studies cannot be overemphasized. In numerous studies a mixture of several 
microvesicle subpopulations is phenotypically and functionally analysed. Such studies are 
difficult to interpret and reproduce and thus must be left out when discussing the function 
of placental exosomes. Thus, the information, reviewed here is taken from a limited number 
of investigations with “maximally pure” exosome fractions isolated from peripheral blood 
of pregnant women (4-8) and placental explant cultures. These studies can be summarized 
as follows: (i) Placental exosomes are able to impair T-cell immune responses by 
downregulation of the intracellular signalling through the CD3-z chain of the accessory 
molecule CD3 and the enzyme Janus kinase 3 (JAK3). (ii) NKG2D ligand-bearing placental 
exosomes act as decoy and downregulate the major activating NK cell receptor NKG2D on 
cytotoxic T-, NK- and T cells with a consequent impairment of the maternal cytotoxicity 
and protection of the fetal allograft against maternal cytotoxic immune attack. (iii) Placental 
exosomes carry the apoptosis-inducing molecules FasL, TRAIL and PD-L1 in active 
functional form that is able to induce apoptosis in activated immune cells. Thus it is clear 
that placental exosomes are involved in the control of critical immune mechanisms such as 
cytotoxicity, T cell response and apoptosis in the local vicinity and /or at a distance from the 
feto-maternal interface. These functions define the placental exosomes as immunosuppressive, 
using in a redundant way a number of mechanisms that inhibit the function of the maternal 
immune system during pregnancy and promote the survival of the fetal allograft. In other 
words, placental exosomes are important players in the establishment of the maternal 
tolerance towards the fetus.  
5. Exosomes in amniotic fluid 
Often, when discussing placental exosomes in pregnancy, exosomes in amniotic fluid are 
mentioned and discussed in the same terms as placental exosomes. However, placental 
exosomes and amniotic exosomes differ in origin and function and are thus different 
entities. The placenta specific exosomes are syncytiotrophoblast-derived and are secreted in 
the intervillous space of the chorionic villi directly into the maternal blood and influence the 
www.intechopen.com
 Recent Advances in Research on the Human Placenta 
 
256 
physiological adjustment of the maternal body to the ongoing pregnancy. The amniotic fluid 
stays in the amniotic cavity enveloped in the amniotic membranes and thus does not enter 
the maternal circulation. The fetus constantly produces amniotic fluid, most of which is fetal 
urine, and constantly swallows amniotic fluid throughout the pregnancy. At any 
developmental stage of pregnancy the amount of amniotic fluid is determined by the 
balance between these two processes. Convincing evidence has shown that the main source 
of amniotic fluid exosomes is the fetal kidney and the fetal urinary system. These exosomes 
carry on their surface CD24 as their specific address marker, annexin-1 and kidney markers 
such as aguaprin-2 and have a similar composition to exosomes from the urine of newborn 
infants (37, 39). It is logical to assume that their presence in the amniotic fluid is because of 
the fetal urine production rather than a special role in the immunomodulation of the 
maternal immune system. Amniotic exosomes have their niche and importance in 
monitoring the prenatal development of the renal system and in developing of prenatal 
diagnosis of kidney diseases and genetic malformations in the fetal kidney and urinary tract. 
6. On the role of placental exosomes in human pregnancy: synthesis of facts 
and a proposed exosomal protective mechanism of action 
Summarizing the current scientific data, there is no doubt that the syncytiotrophoblast of the 
human placenta continuously and constitutively produces and secretes exosomes. The 
placental exosomes are: (i) endosomally produced in the multivesicular bodies of the 
syncytiotrophoblast and released directly into the blood and systemic circulation of the 
pregnant women; (ii) pluripotent and immunosuppressive, carrying important bioactive 
molecules such as stress-inducible ligands, proapoptotic molecules, cytokines, other 
signaling molecules, mRNA and miRNA, thus being able to operate through different 
mechanisms and transform/reprogram recipient cells; (iii) acting by proxy to modulate the 
immune response of the mother locally or at a distance thus promoting maternal immune 
tolerance to the fetal allograft. A schematic drawing, suggesting two mechanisms that might 
be used by placental exosomes to alter the maternal immune response at the feto-maternal 
interface are presented in Figure 5. As can be seen, exosomes carrying NKG2D ligands can 
act as a decoy selectively downregulating cytotoxicity by internalization of the NKG2D 
receptor on cytotoxic T and NK cells without affecting the cytolytic machinery of the effector 
cells. Exosomes, bearing FasL, and/or TRAIL can induce apoptosis directed only towards 
activated Fas-expressing immune cells that might comprise a threat to the ongoing 
pregnancy. Furthermore, the exosomes, secreted by the syncytiotrophoblast to the maternal 
blood are most abundant in the intervillous space at the immediate vicinity of the chorion 
villi, where the highest risk for maternal attack and consequently the highest protection 
against the maternal immune cells is needed. The concentration of placental exosomes 
decreases with increasing distance from the placenta. Thus, the continuous secretion of 
exosomes by the syncytiotrophoblast creates an exosomal concentration gradient where the 
maternal immunosuppression and therefore immune protection of the fetus is strongest at 
the border between the syncytiotrophoblast and the maternal blood preventing a direct 
attack by the maternal immune cells. Moreover, the exosome turnover is very short, 
therefore the immunosuppressive influence of the placental exosomes would be “fading 
away” as the maternal blood leaves the placenta and enters the systemic maternal 
circulation. This could be one of the explanations why, although the maternal immune 
system during pregnancy is downregulated, it is not completely blunted. Pregnant women 
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are more sensitive to infections during pregnancy; however, they are still able to mount a 
modified immune response. The temporarily “semi- immunocompromized” maternal defence 
during pregnancy is the price humans have to pay for the elaborate hemochorial mode of 
reproduction, required to provide the huge amount of oxygen and nourishment necessary for 
the fetal development of the highly complicated and sophisticated human brain. Several 
mechanisms work in concert to meet this challenge and modify the maternal immune system 
during pregnancy with a minimized loss of ability to fight infections and convincing evidence 
suggests that secretion of placental exosomes is one of them. The syncytiotrophoblast, 
producing and releasing exosomes puts up a shield around the hemochorial placenta to 
protect it against the risk of maternal immune attack that ultimately will damage the fetus. 
One can imagine that the fetus, together with the placenta, is “embedded” in a cloud of 
exosomes that creates a beneficial and protective milieu for the fetus to grow and develop. 
 
Adapted from reference #10 with permission of Expert Reviews Ltd. 
Fig. 5. Schematic drawing of the human hemochorial placenta and a scenario suggesting 
how the pluripotent syncytiotrophoblast-released exosomes function at the feto-maternal 
border by down regulating the NKG2D receptor on cytotoxic lymphocytes and/or inducing 
apoptosis of activated Fas-expressing lymphocytes. 
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7. Future perspectives 
The exosome research in reproduction is just at its beginning and it is logical to expect that 
more exosome-carried molecules and mechanisms of action will be revealed in the near 
future. Closing this chapter I would like to outline some issues that await elucidation. The 
first one is a detailed differential characterization of the placental exosomes, nanovesicles 
secreted through the endosomal compartment of the syncytiotrophoblast, in contrast to 
MV/STBM, larger vesicles shed by blebbing from the apical surface of the 
syncytiotrophoblast. Today, many investigations are done on mixture of exosomes and 
MV/STBM giving results difficult to interpret, reproduce or compare. The importance of 
adequate techniques for isolation of these two separate vesicle entities cannot be 
overestimated. Another issue is to identify and understand the exact mechanisms that 
govern exosome biogenesis per se both in general and in the placenta. Why and how do 
some MVB become degradative and sort to lysosomes for destruction whilst others are 
transported to the plasma membrane to release exosomes by exocytosis? The mRNA and 
miRNA content in placental exosomes has just started to shape up and needs confirmation 
and additional analyses to find a consensus. Finally, the role of exosomes in pathological 
pregnancies and related diseases, recurrent abortions, infertility and IVF failure awaits 
evaluation. Gaining knowledge in these areas will open possibilities for novel, exosome-
based treatments of pregnancy failure and infertility. As for now, there is enough 
convincing evidence that the constitutively secreted immunosuppressive placental 
exosomes during normal pregnancy mount a protective exosomal shield around the feto-
placental unit and comprise one of the keys for pregnancy success in human reproduction. 
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